Biocartis – Idylla POLE-POLD1 Mutation Assay

The Idylla™ POLE-POLD1 Mutation Assay (RUO)* provides a rapid and reliable solution to close an important gap in oncology research by enabling molecular classification of endometrial cancer samples. Its fully automated solution is capable to detect 99% of the known pathogenic POLE and POLD1 mutations and it demonstrated 98.6% accuracy with 434 endometrial cancer tissue […]

Biocartis – Idylla ThyroidPrint Assay

Idylla™ ThyroidPrint® Assay (RUO)* is a novel RT qPCR-based molecular signature that assesses a gene expression profile. Using a proprietary algorithm, ThyroidPrint provides assessment of indeterminate thyroid nodule cytology, classifying as low or high risk of malignancy.

Biocartis – Idylla for Colorectal Cancer

Biocartis Idylla™ for colorectal cancer The Idylla solution is a revolutionary, fully automated, real-time PCR based molecular testing system designed to offer results in a minimum amount of time.

Think Biocartis Idylla

WHEN TIME MATTERS. THINK BIOCARTIS IDYLLA*. YOUR BIOMARKER TEST RESULTS WITHIN 3 HOURS. The Idylla™ solution is a revolutionary, fully automated, real-time PCR based molecular testing system designed to offer results in a minimum amount of time.

Biocartis – Clinical utility of Idylla EGFR

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. Within 150 minutes and with less than 2 minutes hands-on time, the fully automated Idylla™ EGFR Mutation Test covers 51 mutations in exons 18–21 in a single cartridge

Biocartis – Breast Cancer Portfolio

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. Biocartis is pleased to launch a new breast cancer portfolio: Idylla™ PIK3CA-AKT1 Mutation Assay, APIS Breast Cancer Subtyping Kit and APIS ESR1 Mutations Kit.